Group 1 - The core viewpoint of the article is that Hangzhou Aotai Biotechnology Co., Ltd. has conducted a review of the list of incentive objects for its 2024 restricted stock incentive plan and has confirmed their eligibility according to relevant laws and regulations [1][2] - The incentive objects do not include independent directors, supervisors, shareholders holding more than 5% of the company's shares, actual controllers and their immediate family members, or foreign employees [1][2] - The list of incentive objects for the plan is consistent with the list approved at the company's second extraordinary general meeting in 2024 [1][2] Group 2 - The incentive objects meet the qualifications stipulated by the Company Law, Securities Law, and other relevant regulations, confirming their legal and effective status as incentive recipients [2] - The reserved grant date for the incentive plan is set for August 29, 2025, with a grant price of 26.2993 yuan per share for 188,000 restricted shares to be awarded to 41 eligible incentive objects [2]

Core Points - The company has announced the reserved grant of 188,000 restricted stocks under the 2024 Restricted Stock Incentive Plan, with a grant date set for August 29, 2025 [1][2][16] - The grant price for the restricted stocks has been adjusted from 29.24 yuan per share to 26.2993 yuan per share [5][16] - The incentive plan aims to enhance employee cohesion and operational efficiency, potentially leading to improved business performance [18] Summary by Sections Incentive Plan Overview - The 2024 Restricted Stock Incentive Plan has been approved, and the reserved grant conditions have been met [2][16] - A total of 41 individuals will receive the reserved stocks, which represent approximately 0.24% of the company's total share capital [11][16] Grant Conditions and Procedures - The decision-making process for the stock grant has been completed, including necessary disclosures and approvals from the board and supervisory committee [3][4][16] - The company has confirmed that no disqualifying conditions exist for the incentive recipients, ensuring compliance with relevant laws and regulations [6][16] Performance Metrics - The performance assessment for the incentive plan will be conducted over two fiscal years, with specific revenue and product registration targets set for each vesting period [12][15] - The first vesting period requires a revenue target of 1.05 billion yuan, while the second period requires a target of 1.26 billion yuan [12] Accounting and Financial Impact - The fair value of the restricted stocks will be calculated using the Black-Scholes model, and the associated costs will be amortized over the vesting period [18] - The implementation of the incentive plan is expected to have a positive impact on the company's operational performance and internal value [18]

Core Viewpoint - The company has adjusted the grant price of its 2024 restricted stock incentive plan from 29.24 CNY per share to 26.2993 CNY per share due to the implementation of its profit distribution plan [1][5][6] Group 1: Adjustment Details - The adjustment of the grant price was approved by the company's board and supervisory board during their respective meetings [1][2] - The adjustment was made in accordance with the company's 2024 restricted stock incentive plan and the authorization from the second extraordinary general meeting of shareholders [1][5] - The adjusted grant price reflects the cash dividends distributed to shareholders, calculated as follows: P = P0 - V, where P0 is the original grant price and V is the cash dividend per share [4][5] Group 2: Financial Impact - The adjustment of the grant price is not expected to have a substantial impact on the company's financial condition or operating results [5][6] - The adjustment will not affect the stability of the management team or the continued implementation of the incentive plan [5][6] Group 3: Opinions from Supervisory and Compensation Committees - The supervisory board agrees that the adjustment complies with relevant laws and regulations and does not harm the interests of the company and all shareholders [5][6] - The compensation and assessment committee of the board also supports the adjustment, confirming its compliance with the management regulations and the incentive plan [6]

Core Viewpoint - The legal opinion letter from Shanghai Lifeng Law Firm confirms that Hangzhou Aotai Biotechnology Co., Ltd. has complied with relevant laws and regulations regarding the adjustment of the grant price and the reserved grant of the 2024 restricted stock incentive plan [1][4][13] Group 1: Approval and Authorization - The board of directors approved the adjustment of the grant price from 29.2400 yuan/share to 26.2993 yuan/share for the incentive plan [6][8] - The supervisory board confirmed that the adjustment process was legal and compliant with regulations, and the reserved grant date was set for August 29, 2025, for 188,000 shares to 41 eligible recipients [6][9] Group 2: Specifics of the Adjustment - The company plans to distribute cash dividends of 1.50 yuan per share, totaling 116,802,501 yuan, based on a total share capital of 79,280,855 shares [8] - The adjustment of the grant price was approved during meetings held on August 29, 2025, and the new price reflects compliance with the management regulations [7][9] Group 3: Grant Conditions and Recipients - The grant conditions have been met, and the recipients of the reserved stock are in accordance with the relevant laws and regulations [11][13] - The board confirmed that the grant date and recipients comply with the management regulations and the incentive plan [9][12]

证券代码：688606 证券简称：奥泰生物 公告编号：2025-034 杭州奥泰生物技术股份有限公司 第三届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况： 杭州奥泰生物技术股份有限公司（以下简称"公司"）第三届监事会第十五次会 议（以下简称"本次会议"）于 2025 年 8 月 20 日以电子邮件的形式发出会议通知， 于 2025 年 8 月 29 日上午 9：30 在公司会议室以现场会议的方式召开。会议应出席监 事 3 名，实际出席监事 3 名。本次会议的召集、召开程序和方式符合《中华人民共和 国公司法》（以下简称"《公司法》"）等法律法规以及《杭州奥泰生物技术股份有 限公司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况： 会议由监事会主席高跃灿先生主持召开，全体与会监事经认真审议和表决，形成 以下决议： 1、审议通过《关于<调整 2024 年限制性股票激励计划授予价格>的议案》 鉴于公司 2024 年半年度及 2024 年 ...

Group 1 - The core viewpoint of the article is that Aotai Biologics (688606.SH) reported its semi-annual results for 2025, showing positive growth in revenue and net profit [1] - The company achieved an operating income of 430 million yuan, representing a year-on-year increase of 8.41% [1] - The net profit attributable to shareholders of the listed company was 132 million yuan, reflecting a year-on-year growth of 6.57% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 109 million yuan, which is a year-on-year increase of 17.27% [1] - The basic earnings per share were reported at 1.67 yuan [1]

证券代码：688606 证券简称：奥泰生物 公告编号：2025-033 杭州奥泰生物技术股份有限公司 第三届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州奥泰生物技术股份有限公司（以下简称"公司"）第三届董事会第十五 次会议（以下简称"本次会议"）于 2025 年 8 月 20 日以电子邮件的方式发出会 议通知，于 2025 年 8 月 29 日上午 11：00 在公司会议室以现场与通讯相结合的 方式召开。本次会议由公司董事长高飞先生召集并主持，本次会议应出席董事 5 名，实际出席董事 5 名，高级管理人员列席了本次会议。本次会议的召开符合《中 华人民共和国公司法》等法律法规以及《杭州奥泰生物技术股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事充分讨论，审议并表决如下议案： 1、审议通过《关于<调整 2024 年限制性股票激励计划授予价格>的议案》 限制性股票的议案》 《2024 年激励计划》规定的 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-036 杭州奥泰生物技术股份有限公司 关于向 2024 年限制性股票激励计划激励对象 授予预留部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●限制性股票预留授予日：2025 年 8 月 29 日； ●限制性股票预留授予数量：18.80 万股，约占公司目前股本总额 7,928.0855 万股的 0.24%； ●股权激励方式：第二类限制性股票。 根据《杭州奥泰生物技术股份有限公司 2024 年限制性股票激励计划（草案）》 （以下简称"《2024 年激励计划》"）的规定，杭州奥泰生物技术股份有限公 司（以下简称"公司"）2024 年限制性股票预留授予条件已经成就，根据公司 2024 年第二次临时股东大会的授权，公司于 2025 年 8 月 29 日召开第三届董事会薪酬 与考核委员会第九次会议、第三届董事会第十五次会议、第三届监事会第十五次 会议，审议通过了《关于向 2024 年限制性股票激励计划激励对象授予预留部分 限制性股票 ...

杭州奥泰生物技术股份有限公司 关于公司 2024 年限制性股票激励计划预留授予 激励对象的核查意见 杭州奥泰生物技术股份有限公司（以下简称"公司"）监事会根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板 上市公司自律监管指南第 4 号——股权激励信息披露》等有关法律法规及规范 性文件以及《公司章程》的有关规定，对公司 2024 年限制性股票激励计划（以 下简称"激励计划"）预留授予激励对象名单进行核查，并发表核查意见如下： （一）本次激励计划预留授予的激励对象均不存在《管理办法》规定的不 得成为激励对象的情形： 1、最近12个月内被证券交易所认定为不适当人选； （二）本次激励计划预留授予的激励对象不包括公司独立董事、监事、单 独或合计持有公司5%以上股份的股东、公司实际控制人及其配偶、父母、子女， 亦不包括外籍员工。 （三）本激励计划预留授予激励对象人员名单与公司2024年第二次临时股 东大会批准的激励计划中规定的 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-035 杭州奥泰生物技术股份有限公司 关于调整 2024 年限制性股票激励计划 授予价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●限制性股票授予价格（含预留）：由 29.24 元/股调整为 26.2993 元/股； 杭州奥泰生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日召开的第三届董事会第十五次会议和第三届监事会第十五次会议，审议通过了 《关于调整 2024 年限制性股票激励计划授予价格的议案》。根据《杭州奥泰生 物技术股份有限公司 2024 年限制性股票激励计划（草案）》（以下简称"《2024 年激励计划》"）的相关规定及公司 2024 年第二次临时股东大会授权，董事会 对公司 2024 年限制性股票激励计划（以下简称"本次激励计划"）的授予价格 进行调整。授予价格（含预留部分）由 29.24 元/股调整为 26.2993 元/股。现将有 关事项说明如下： 一、本激励计划已履行的决策程序和信息披露情 ...